UPDATE : Monday, August 3, 2020
HOME Pharma
Daewoong unveils trial results for anti-ulcer agent
  • By Lee Han-soo
  • Published 2018.04.23 11:48
  • Updated 2018.04.23 11:48
  • comments 0
Professor Lee Jong-wook presents the domestic phase 1 clinical trial results for DWP14012 at the 7th Asian Postgraduate Course on Neurogastroenterology and Motility (APNM 2018).

Daewoong Pharmaceutical said Monday that it has presented phase 1 clinical trial results for DWP14012, an anti-ulcer drug candidate, at the 7th Asian Postgraduate Course on Neurogastroenterology and Motility (APNM 2018) in Seoul.

DWP14012 is a gastric pump antagonist with a reversible inhibition mechanism. The company expects that the drug will replace the conventional proton pump inhibitor (PPI) agent, which inhibits the proton pump that controls gastric acid release. PPI is a representative inhibitor of gastric acid secretion.

During the presentation, the company unveiled the drug’s nonclinical and clinical data, which revealed that the candidate is a safe gastric pump antagonist that has excellent drug effect compared when compared with PPI through nonclinical and clinical data. Also, the results of the hepatotoxicity biomarker in phase 1 clinical trial showed promising results of developing a safe next-generation anti-ulcer agent.

“In addition to the fast drug efficacy time, based on P-CAB, DWP14012 showed excellent nighttime acid secretion inhibition compared to the other conventional drugs,” said Professor Lee Seung-hwan of the department of clinical pharmacology at Seoul National University Hospital (SNUH). “We expect that the drug will improve patient compliance and metabolism through various routes as it has no dietary restrictions.”

Daewoong also presented its determination to develop the drug as soon as possible.

“Through this symposium, we believe we have raised the expectation of domestic and foreign digestive system specialists and scholars for the development of a next-generation anti-ulcer agent,” Daewoong CEO Jeon Seng-ho said. “To meet such expectations, clinical trials are underway to accelerate reflux esophagitis as well as to obtain indications for various acid secretions for the drug.”

The company also expects that active partnership for rapid commercialization in the global market will also accelerate, Jeon added.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top